UPDATE: Citigroup Reiterates on Medtronic Following Solid F2Q14 Results

In a report published Thursday, Citigroup analyst Matthew J. Dodds reiterated a Buy rating on

, and raised the price target from $62.00 to $69.00. In the report, Citigroup noted, “F2Q14 results were slightly ahead of Street expectations driven by ICD upside, lower non-operating expense and a lower share count. F2014 guidance was maintained as the drivers are rotating and expect multiple expansion to continue as investor focus shifts to F2015. Sales of $4.194B (+2.4%) were $15MM ahead of the consensus view. Excluding FX (-90bp) and acquisitions (+30bp), organic sales growth was 3.1%, or 80bp below the industry average for the quarter. ICDs (+4% cc) were $30MM ahead of the Street but was offset by a $28MM shortfall in Spine (-3% cc). Diabetes (+3% cc) was slightly better than expected behind the mid-October US launch of the 530G pump. Neuromodulation (+6% cc), Surgical Tech (+10% cc), Pacemakers (+2% cc) and Cardiovascular (+3% cc) were all in line. EM growth of 13% cc was a touch below F1Q14 (+15% cc) and F4Q13 (+14% cc) as China and Russia were below plan.” Medtronic closed on Wednesday at $56.89.